PlantForm Corporation
PlantForm is a biotechnology company headquartered in Guelph, Ontario, Canada, with a proven technology used to develop and manufacture high value proteins and antibodies as diagnostics, drugs, and vaccines. PlantForm’s patented vivoXPRESS® technology uses genetically modified tobacco plants to manufacture very low-cost products using fully contained vertical growth environments. The company is revenue generating from contracts including production of components for COVID-19 diagnostic kits. The proceeds of the financing will advance company's lead medical countermeasure drug through IND enabling and Phase 1 Clinical Studies to enter the market in 2-3 years, no Phase 2 or 3 Clinical trials being required.
Presenter: Don Stewart, CEO
Read More
PROTXX
PROTXX enhances care, outcomes, and healthcare economics for patients living with neuro-disruptive (e.g. concussion, stroke) and neuro-degenerative (e.g. multiple sclerosis, Parkinson’s disease) medical conditions. Our precision health platform integrates innovations in non-invasive wearable physiological sensors and machine learning classification of neurosensory and neuromotor impairments, replacing complex clinical equipment and time-consuming tests with easier-to-use, lower-cost, in-clinic and remote precision patient assessments. At the core of the PROTXX platform is the company’s “phybrata” sensor, a tiny, non-invasive device worn behind the ear that is able to classify, quantify, and monitor impairments to the major neurophysiological systems in the body.
Presenter: John Ralston, CEO and Founder
Read More
Providence Therapeutics
Providence Therapeutics has successfully raised over $10.7 million over the last year to support its personalized cancer vaccine program, using it mRNA vaccine technology. Since the COVID-19 pandemic, we have redeployed our GMP production capacity to develop and manufacture a made-in-Canada COVID-19 mRNA vaccine. We have clinical trials planned for early 2021 that are supported by the NRC. Scale-up of our vaccine is currently underway and is supported by $3.5 million in contributions from the NGen supercluster. The proceeds from our series B will support continued Phase 2 clinical trials and scaled production to support commercialization.
Presenter: Brad Sorenson, CEO
Read More
Realize Medical
Realize Medical is the creator of Elucis, the only all-in-one 3D medical modelling solution offering true 3D precision input, visualization and multi-user collaboration, entirely in VR. After getting into early stage revues in the research use stage, RM is raising $1.5m in seed funding to expand sales and engineering teams, achieve FDA clearance and provide 18+ months runway.
Presenter: Taylor Fantin, CFO
Read More
Replica Analytics
Replica Analytics develops data synthesis technology. This allows data simulators to be created – these are models that can be used to generate new data while retaining the statistical properties and patterns in the original data. A key use case of data simulators is to provide rapid access to clinical data within the enterprise, and to augment small studies (i.e., use 50% of the target recruitment to simulate the remaining 50%). Data augmentation can change the economics of clinical studies by allowing the same conclusions to be drawn from smaller datasets.
Hear more from this company during the Early Technology Showcase.
Presenter: Khaled El Emam, Co-founder and Director
Read More
Ripple Therapeutics
Ripple Therapeutics is a clinical stage company focused on improving ophthalmic therapeutics with controllable, sustained drug delivery. Ripple’s Epidel® platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor drug dose and duration to the specific indication. Ripple’s lead program – IBE-814 IVT – is an intravitreal implant targeting diabetic macular edema (DME) and retinal vein occlusion (RVO). A Phase II trial has been initiated in Australia with the first patient treatment expected early 2021.
Presenter: Wendy Naimark, VP, Research & Development
Read More
Rna Diagnostics
Rna Diagnostics is a clinical-stage company developing it’s first product, a proprietary diagnostic test for breast cancer therapy response measurement. Our test will indicate to doctors, early in treatment, which patients will receive a survival benefit and which patients will not. This test will help address the $60 billion that is spent each year on cancer drugs that are not working for a majority of patients.
Presenter: Jeremy Bridge-Cook, President & CEO
Read More
Specific Biologics
Specific Biologics is a discovery stage company developing platform gene editing technologies as therapeutics to treat or cure disease through precision gene editing. Our gene editor Dualase is designed to overcome two problems with current gene editor – random DNA insertions / deletions and low frequency repair. Unlike other technologies, Dualase cuts DNA in two spots and leaves non-compatible DNA ends. These ends create precise deletions to disrupt DNA or increase rates of repair to correct DNA. We are raising $2.7 million CAD to advance our programs in cystic fibrosis and oncology in preclinical animal models and further develop the platform.
Presenter: Brent Stead, CEO
Read More
Spiderwort
Spiderwort is an innovative pre-clinical stage tissue engineering company specializing in the development of cellulose-based biomaterials with a lead indication in Spinal Cord Injury repair with the ultimate goal to improve human quality of life. The FDA has granted a Breakthrough Device Designation for Spiderwort’s spinal cord technology. Spiderwort is raising Series A capital to support clinical pilot studies.
Presenter: Charles Cuerrier, CEO
Read More
Steadiwear
Steadiwear develops battery-free gloves that stabilizes hand tremors in Parkinson’s disease & Essential tremor using technology was inspired by leading-edge earthquake dampers used in buildings. We are raising seed funding for clinical trial & health economics studies, manufacturing, and sales and marketing.
Presenter: Mark Elias, CEO
Read More
Synergy Disc Replacement
SDRi is a Canadian spinal medical device company pioneering a revolutionary artificial disc replacement implant technology - the only artificial disc implant that can both preserve motion and restore alignment to the spine. With a CE mark, Synergy has begun early commercialization efforts in last couple years in Europe and Australia. We have completed more than 1000 implants of the Synergy Disc with no device related adverse events. Synergy is now raising $15M USD to complete its FDA IDE clinical trial in pursuit of USA market approval, the largest market in the world for cervical artificial disc implants.
Presenter: Josh Butters, CEO
Read More
Synmedix
Synmedix is a newly-founded biotechnology company created to commercialize a novel platform that dramatically enhances the effectiveness of antibiotics to address unmet medical need posed by the global health crisis in antibiotic resistance. Synmedix was founded on McMaster University technology, showing that bicarbonate dramatically improves the efficacy and spectrum of several antibiotics enabling the treatment of multidrug-resistant infections. Synmedix is seeking seed funding for preclinical studies leading to an Investigational New Drug (IND) for its lead product BCX-4, azithromycin plus bicarbonate, for a first-in-class treatment of diabetic foot ulcer infections. Clinical development will leverage the FDA’s accelerated 505(b)(2) pathway.
Presenter: Eric Brown, CEO
Read More
TATUM Bioscience
TATUM Bioscience is a synthetic biology startup developing a new class of drug called synthetic live biotherapeutics (synLBT). synLBT are probiotics engineered to execute advanced therapeutic tasks. This technology disrupts the conventional drug development process by allowing us to build drugs instead of discovering them. Using its unique modular platform, TATUM design synLBTs to tackle diseases for which conventional drugs have now reached their limits and focuses its efforts on antibiotic resistance and oncology. The company will open a seed round in Q4 of 2021 to advance its programs, expand its IP portfolio, and conduct INTERACT and pre-IND meetings.
Presenter: Jean-François Millau, CEO
Read More
TCRyption Inc.
TCRyption Inc., a novel TCR-T cell therapy company, with the goal of expanding the availability of T-cell receptor based cellular therapeutic (TCR-T) options as effective and safe therapies across multiple cancers with a high unmet need. The company’s highly diverse and growing TCR bank utilizes the proprietary TCRypt platform, originally created by Dr. Naoto Hirano at University Health Network’s (UHN) Princess Margaret Cancer Centre. With unparalleled sensitivity in its ability to mine physiologically relevant TCR’s, this platform enables the rapid discovery of an expansive bank of TCRs that can be used to better address patient needs. TCRyption was established with an initial $10 million in seed financing from TIO Bioventures.
Presenter: Michael Tusche, Co-CEO
Read More
Treadwell Therapeutics
Treadwell Therapeutics is a clinical stage Biotechnology company, driven by novel science, and focused on the development of First in class, best in class or only in class small molecule candidates for unmet needs in oncology. Co-Founded in July of 2019 by Drs. Tak Mak and Mark Bray, Treadwell’s three clinical stage assets have been in development for over a decade by the Therapeutics group at the Campbell Family Institute at UHN. With operations in New York, Boston, San Francisco, Hong Kong, and a substantial footprint in Toronto, Treadwell has a global view and strong local roots. The company was established with a $25M investment from TIO Bioventures.
Presenter: Michael Tusche, Co-CEO
Read More
Virica
At Virica, we believe that viral medicines hold the key to unlocking the future of human healthcare. However, there are unmet needs in the field of viral therapeutics that limit their development and scalability. Virica fills this void through our proprietary viral sensitizer or VSE technology, in order to realize the promise of viral medicines to extend the horizons of human healthcare. We deploy and monetize our versatile VSE small molecules by working with vaccine and gene therapy manufacturers to reduce their cost of goods, and by developing a pipeline of enhanced viral therapeutics for cancer and other diseases.
Presenter: Jean-Simon Diallo, Scientific Founder/CEO
Read More
VitalTracer
VitalTracer is a start-up whose focus is on healthcare in the domain of personalized medicine. We aim to create a platform for those who need to improve or manage health with a convenient and non-invasive solution. VitalTracer has raised about 1 million in non-dilutive financing and is currently boot-strapping. We will open our seed round in summer 2021 which will cover our expenses of Research and Development, Regulatory clearance for Health Canada and FDA, manufacturing and clinical validation.
Presenter: Azadeh Dastmalchi, CEO
Read More
Zucara Therapeutics Inc.
Zucara Therapeutics Inc. is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with insulin dependent diabetes. ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. Zucara has recently raised US$21M in a Series A financing that provides capital to conduct Phase 1 and 2 clinical trials. Phase 1 trials are underway with results expected in 2021. For more information, visit www.zucara.ca.
Presenter: Michael Midmer, CEO
Read More
